"This approval provides another treatment choice for patients with these rare cancers."Īs well as adding Lutathera and 177Lu-PSMA-R2 (in Phase 1/2 study in prostate cancer) to Novartis' oncology portfolio, the acquisition of Advanced Accelerator Applications also brings on board a portfolio of diagnostics. "GEP-NETs are a rare group of cancers with limited treatment options after initial therapy fails to keep the cancer from growing," commented Richard Pazdur, director of the FDA's Oncology Center of Excellence, in a Jan. They include Tarveda Therapeutics Inc.'s PEN-221, which targets the somatostatin receptor and carries a potent cytotoxic, and is expected to move into Phase 2a in first quarter of 2018 and OctreoPharm Sciences GmbH's 177Lu-OPS201 PRRT, which has been assessed under compassionate use in a pilot study. Novartis se renforce dans la médecine nucléaire moléculaire. There are a few other companies developing therapeutics for NETs. Le groupe bâlois va débourser 3,9 milliards de dollars pour lentreprise française Advanced Accelerator Applications (AAA). Roughly one in 27,000 people are diagnosed with GEP-NETs each year, and patients with neuroendocrine tumors with distant metastases have a five-year survival probability of around 35%. "For 30 years, Novartis has supported the NET community with the development of therapeutics in NET and carcinoid syndrome," said Susanne Schaffert, chair and president, Advanced Accelerator Applications, in a statement.
Objective response rate, composed of complete and partial responses, was 13% for the Lutathera arm compared to 4% in the Octreotide LAR arm. In the NETTER-1 study, median progression-free survival had not been reached in the Lutathera arm, versus 8.5 months for the 60 mg octreotide LAR arm. Mr.Novartis acquired Advanced Accelerator for $3.9 billion last October, closing the deal last week - just in time for the FDA's target decision date for the nuclear medicine company's lead radioligand therapy, Lutathera (lutetium Lu 177 dotatate). Novartis already sells a drug called Afinitor that treats a range of cancers including neuroendocrine tumors. The two most important of these are Cosentyx for psoriasis and certain rheumatoid conditions and Entresto for heart failure.īruno Strigini, head of Novartis Oncology, said the acquisition would allow the company to expand the global reach of Lutathera. Novartis is also counting on new drug launches in other disease areas to offset Gleevec’s decline. AAA’s flagship product, Lutathera, won European Union backing in late September for use against gastroenteropancreatic neuroendocrine tumors, the kind of cancer that killed Apple founder Steve Jobs. Novartis would gain Lutathera (177-Lu-Dotatate), a radiolabeled somatostatin analog that targets somatostatin receptors, and its companion diagnostics SomaKit TOC edotreotide and Netspot. That in itself fits into Novartis’ burgeoning cancer business. The Swiss pharma giant has agreed to shell out $3.9 billion, or $41 per share, for AAA, whose current products are radioactive tracers used in diagnostic scans. Swiss drugmaker, Novartis, has now entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which it intends to commence a tender offer for 100 percent of the share capital of AAA subject to certain conditions. Our expertise is built on a more than 15-year legacy of manufacturing and commercializing a portfolio of PET and SPECT nuclear medicine imaging products for a number of indications in oncology, neurology. Novartis to Acquire French Advanced Accelerator Applications for $3.9B Advanced Accelerator Applications develops, produces and commercializes drugs for targeted radioligand therapy and precision radioligand imaging.
0 kommentar(er)
